Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Эффективность двухкомпонентной блокады ренин-ангиотензин-альдостероновой системы после трансплантации почки у пациентов с терминальной хронической почечной недостаточностью - Научно-практический журнал Cardioсоматика Том 6, №4 (2015)
Эффективность двухкомпонентной блокады ренин-ангиотензин-альдостероновой системы после трансплантации почки у пациентов с терминальной хронической почечной недостаточностью
Останина А.А., Фомин И.В., Поляков Д.С. и др. Эффективность двухкомпонентной блокады ренин-ангиотензин-альдостероновой системы после трансплантации почки у пациентов с терминальной хронической почечной недостаточностью. КардиоСоматика. 2015; 6 (4): 22–27.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Проведено исследование по определению эффективности и безопасности снижения артериального давления (АД) у больных после трансплантации почки с использованием двухкомпонентной блокады ренин-ангиотензин-альдостероновой системы (РААС). В течение полугода после трансплантации почки отмечается у 51,6% пациентов синдром ускользания контроля АД; 13 пациентов после трансплантации (69,2% мужчин и 30,8% женщин; средний возраст 34,7±11,8 года), имеющих хронический гломерулонефрит (100% случаев) как основную причину терминальной стадии хронической болезни почек, после подписания информированного согласия начали принимать алискирен в дозе 150–300 мг в комбинации с сартаном и антагонистом кальция. В течение 2 мес лечения установлена нормализация АД до АД<130/80 мм рт. ст. Выявлены прямая достоверная корреляционная зависимость между снижением АД и ухудшением функции трансплантата за счет снижения скорости клубочковой фильтрации, тенденция к повышению индекса резистентности дуговых и центральных сосудов трансплантированной почки, увеличения протеинурии. Двухмесячная терапия алискиреном и сартаном оказалась безопасной в плане действия на минеральный, углеводный, белковый обмены.
Ключевые слова: трансплантация почки, артериальная гипертония, комбинированная гипотензивная терапия.
Key words: kidney transplantation, arterial hypertension, combination therapy.
Ключевые слова: трансплантация почки, артериальная гипертония, комбинированная гипотензивная терапия.
________________________________________________
Key words: kidney transplantation, arterial hypertension, combination therapy.
Полный текст
Список литературы
1. Clase CM, Garg AX, Kiberd BA. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol 2002; 13 (5): 1338–49.
2. Бикбов Б.Т., Томилина Н.А. Состояние заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998–2009 гг. (Отчет по данным Российского регистра заместительной почечной терапии). Нефрология и диализ. 2011; 13 (3). / Bikbov B.T., Tomilina N.A. Sostoianie zamestitel'noi terapii bol'nykh s khronicheskoi pochechnoi nedostatochnost'iu v Rossiiskoi Federatsii v 1998–2009 gg. (Otchet po dannym Rossiiskogo registra zamestitel'noi pochechnoi terapii). Nefrologiia i dializ. 2011; 13 (3). [in Russian]
3. Campistol JM, Romero R, Paul J, Gutieґrrez-Dalmaul А. Epidemiology of arterial hypertension in renal transplant patients: changes over the last decade. Nephrol Dial Transplant 2004; 19 (Suppl. 3): 62–6.
4. Kasiske BL, Cangro CB, Hariharan S et al. American Society of Transplantation. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2001; 1 (Suppl. 2): 3–95.
5. Curtis JJ. Hypertensinogenic mechanism of the calcineurin inhibitors. Curr Hypertens Rep 2002; 4: 377–80.
6. Mangus RS, Haag BW. Stented versus nonstented extravesical ureteroneocystostomy in renal transplantation: a metaanalysis. Am J Transplant 2004; 4 (11): 1889–96.
7. Pampaloni F, Sanchez LJ, Bencini L, Taddei G. Simultaneous aortoiliac reconstruction and renal transplantation: is it safe? Chir Ital 2002; 54(1): 115–20.
8. Cornell LD, Smith RN, Colvin RB. Kidney transplantation: mechanisms of rejection and acceptance. Annu Rev Pathol 2008; 3: 189–220.
9. Tomasoni S, Remuzzi G, Benigni A. Allograft rejection: acute and chronic studies. Contrib Nephrol 2008; 159: 122–34.
10. Webster AC, Woodroffe RC, Taylor RS et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331 (7520): 810.
11. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81 (9): 1234–48.
12. Lassila M. Interaction of cyclosporine A and the reninangiotensin system; new perspectives. Curr Drug Metab 2002; 3: 61–71.
13. Segura J, Garcia-Donair J, Praga M et al. Chronic kidney disease as a situation of high added risk in hypertensive patients J Am Soc Nephrol 2006; 17 (Suppl. 2.): 136–40.
14. Foley R, Murray A, Li S et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489–95.
15. Hausberg M, Kosch M, Hohage H et al. Antihypertensive treatment in renal transplant patients – is there a role for ACE inhibitors? Ann Transplant 2001; 6: 31–7.
16. Baroletti SA, Gabardi S, Magee CC, Milford EL. Calcium channel blockers as the treatment of choice for hypertension in renal transplant recipients: fact or fiction. Pharmacotherapy 2003; 23: 788–801.
17. Noris M, Mister M, Pezzotta A et al. ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. Kidney Int 2003; 64: 2253–61.
18. Cross NB, Webster AC, Masson P et al. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 2009; 88: 7–18.
19. Parving HH, Persson F, Lewis JB et al. Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. N Engl J Med 2008; 358: 2433–46.
20. Persson F, Lewis JB, Lewis EJ et al. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol 2011; 6 (5): 1025–31.
21. Gansevoort RT, Sluiter WJ, Hemmelder MH et al. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10 (11): 1963–74.
22. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 259–305.
23. Del Castillo D, Campistol JM, Guirado L et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int Suppl 1998; 68: S135–S139.
24. Фомин И.В., Останина А.А., Поляков Д.С., Липатов К.С. Существует ли оптимальный уровень артериального давления у пациентов с терминальной хронической почечной недостаточностью до и после трансплантации почки? Совр. технологии в медицине. 2014; 6 (2): 53–60. / Fomin I.V., Ostanina A.A., Poliakov D.S., Lipatov K.S. Sushchestvuet li optimal'nyi uroven' arterial'nogo davleniia u patsientov s terminal'noi khronicheskoi pochechnoi nedostatochnost'iu do i posle transplantatsii pochki? Sovr. tekhnologii v meditsine. 2014; 6 (2): 53–60. [in Russian]
25. Paoletti E, Gherzi M, Amidone M et al. Association of arterial hypertension with renal target organ damage in kidney transplant recipients: the predictive role of ambulatory blood pressure monitoring. Transplantation 2009; 87: 1864–9.
26. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53: 217–22.
27. Мухин Н.А., Балкаров И.М., Моисеев В.С. и др. Хронические прогрессирующие нефропатии и образ жизни современного человека. Терапевт. арх. 2004; 9: 5–10. / Mukhin N.A., Balkarov I.M., Moiseev V.S. i dr. Khronicheskie progressiruiushchie nefropatii i obraz zhizni sovremennogo cheloveka. Terapevt. arkh. 2004; 9: 5–10. [in Russian]
28. Кобалава Ж.Д., Котовская Ю.В., Толкачева В.В., Мильто А.С. Мочевая кислота – ключевой компонент кардиренометаболического континуума. Кардиоваск. терапия и профилактика. 2008; 4: 95–100. / Kobalava Zh.D., Kotovskaia Iu.V., Tolkacheva V.V., Mil'to A.S. Mochevaia kislota – kliuchevoi komponent kardirenometabolicheskogo kontinuuma. Kardiovask. terapiia i profilaktika. 2008; 4: 95–100. [in Russian]
29. Parving HH, Brenner BM, McMurray JJV et al. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204–13.
30. Parving HH, Brenner BM, McMurray JJ et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst 2012; 13 (3): 387–93.
31. Mann JFE, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind controlled trial. Lancet 2008; 372: 547–53.
32. Inigo P, Campistol JM, Lario S et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta (1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 2001; 12: 822–7.
2. Bikbov B.T., Tomilina N.A. Sostoianie zamestitel'noi terapii bol'nykh s khronicheskoi pochechnoi nedostatochnost'iu v Rossiiskoi Federatsii v 1998–2009 gg. (Otchet po dannym Rossiiskogo registra zamestitel'noi pochechnoi terapii). Nefrologiia i dializ. 2011; 13 (3). [in Russian]
3. Campistol JM, Romero R, Paul J, Gutieґrrez-Dalmaul А. Epidemiology of arterial hypertension in renal transplant patients: changes over the last decade. Nephrol Dial Transplant 2004; 19 (Suppl. 3): 62–6.
4. Kasiske BL, Cangro CB, Hariharan S et al. American Society of Transplantation. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2001; 1 (Suppl. 2): 3–95.
5. Curtis JJ. Hypertensinogenic mechanism of the calcineurin inhibitors. Curr Hypertens Rep 2002; 4: 377–80.
6. Mangus RS, Haag BW. Stented versus nonstented extravesical ureteroneocystostomy in renal transplantation: a metaanalysis. Am J Transplant 2004; 4 (11): 1889–96.
7. Pampaloni F, Sanchez LJ, Bencini L, Taddei G. Simultaneous aortoiliac reconstruction and renal transplantation: is it safe? Chir Ital 2002; 54(1): 115–20.
8. Cornell LD, Smith RN, Colvin RB. Kidney transplantation: mechanisms of rejection and acceptance. Annu Rev Pathol 2008; 3: 189–220.
9. Tomasoni S, Remuzzi G, Benigni A. Allograft rejection: acute and chronic studies. Contrib Nephrol 2008; 159: 122–34.
10. Webster AC, Woodroffe RC, Taylor RS et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331 (7520): 810.
11. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81 (9): 1234–48.
12. Lassila M. Interaction of cyclosporine A and the reninangiotensin system; new perspectives. Curr Drug Metab 2002; 3: 61–71.
13. Segura J, Garcia-Donair J, Praga M et al. Chronic kidney disease as a situation of high added risk in hypertensive patients J Am Soc Nephrol 2006; 17 (Suppl. 2.): 136–40.
14. Foley R, Murray A, Li S et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489–95.
15. Hausberg M, Kosch M, Hohage H et al. Antihypertensive treatment in renal transplant patients – is there a role for ACE inhibitors? Ann Transplant 2001; 6: 31–7.
16. Baroletti SA, Gabardi S, Magee CC, Milford EL. Calcium channel blockers as the treatment of choice for hypertension in renal transplant recipients: fact or fiction. Pharmacotherapy 2003; 23: 788–801.
17. Noris M, Mister M, Pezzotta A et al. ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. Kidney Int 2003; 64: 2253–61.
18. Cross NB, Webster AC, Masson P et al. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 2009; 88: 7–18.
19. Parving HH, Persson F, Lewis JB et al. Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. N Engl J Med 2008; 358: 2433–46.
20. Persson F, Lewis JB, Lewis EJ et al. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol 2011; 6 (5): 1025–31.
21. Gansevoort RT, Sluiter WJ, Hemmelder MH et al. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10 (11): 1963–74.
22. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 259–305.
23. Del Castillo D, Campistol JM, Guirado L et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int Suppl 1998; 68: S135–S139.
24. Fomin I.V., Ostanina A.A., Poliakov D.S., Lipatov K.S. Sushchestvuet li optimal'nyi uroven' arterial'nogo davleniia u patsientov s terminal'noi khronicheskoi pochechnoi nedostatochnost'iu do i posle transplantatsii pochki? Sovr. tekhnologii v meditsine. 2014; 6 (2): 53–60. [in Russian]
25. Paoletti E, Gherzi M, Amidone M et al. Association of arterial hypertension with renal target organ damage in kidney transplant recipients: the predictive role of ambulatory blood pressure monitoring. Transplantation 2009; 87: 1864–9.
26. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53: 217–22.
27. Mukhin N.A., Balkarov I.M., Moiseev V.S. i dr. Khronicheskie progressiruiushchie nefropatii i obraz zhizni sovremennogo cheloveka. Terapevt. arkh. 2004; 9: 5–10. [in Russian]
28. Kobalava Zh.D., Kotovskaia Iu.V., Tolkacheva V.V., Mil'to A.S. Mochevaia kislota – kliuchevoi komponent kardirenometabolicheskogo kontinuuma. Kardiovask. terapiia i profilaktika. 2008; 4: 95–100. [in Russian]
29. Parving HH, Brenner BM, McMurray JJV et al. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204–13.
30. Parving HH, Brenner BM, McMurray JJ et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst 2012; 13 (3): 387–93.
31. Mann JFE, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind controlled trial. Lancet 2008; 372: 547–53.
32. Inigo P, Campistol JM, Lario S et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta (1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 2001; 12: 822–7.
2. Бикбов Б.Т., Томилина Н.А. Состояние заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998–2009 гг. (Отчет по данным Российского регистра заместительной почечной терапии). Нефрология и диализ. 2011; 13 (3). / Bikbov B.T., Tomilina N.A. Sostoianie zamestitel'noi terapii bol'nykh s khronicheskoi pochechnoi nedostatochnost'iu v Rossiiskoi Federatsii v 1998–2009 gg. (Otchet po dannym Rossiiskogo registra zamestitel'noi pochechnoi terapii). Nefrologiia i dializ. 2011; 13 (3). [in Russian]
3. Campistol JM, Romero R, Paul J, Gutieґrrez-Dalmaul А. Epidemiology of arterial hypertension in renal transplant patients: changes over the last decade. Nephrol Dial Transplant 2004; 19 (Suppl. 3): 62–6.
4. Kasiske BL, Cangro CB, Hariharan S et al. American Society of Transplantation. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2001; 1 (Suppl. 2): 3–95.
5. Curtis JJ. Hypertensinogenic mechanism of the calcineurin inhibitors. Curr Hypertens Rep 2002; 4: 377–80.
6. Mangus RS, Haag BW. Stented versus nonstented extravesical ureteroneocystostomy in renal transplantation: a metaanalysis. Am J Transplant 2004; 4 (11): 1889–96.
7. Pampaloni F, Sanchez LJ, Bencini L, Taddei G. Simultaneous aortoiliac reconstruction and renal transplantation: is it safe? Chir Ital 2002; 54(1): 115–20.
8. Cornell LD, Smith RN, Colvin RB. Kidney transplantation: mechanisms of rejection and acceptance. Annu Rev Pathol 2008; 3: 189–220.
9. Tomasoni S, Remuzzi G, Benigni A. Allograft rejection: acute and chronic studies. Contrib Nephrol 2008; 159: 122–34.
10. Webster AC, Woodroffe RC, Taylor RS et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331 (7520): 810.
11. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81 (9): 1234–48.
12. Lassila M. Interaction of cyclosporine A and the reninangiotensin system; new perspectives. Curr Drug Metab 2002; 3: 61–71.
13. Segura J, Garcia-Donair J, Praga M et al. Chronic kidney disease as a situation of high added risk in hypertensive patients J Am Soc Nephrol 2006; 17 (Suppl. 2.): 136–40.
14. Foley R, Murray A, Li S et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489–95.
15. Hausberg M, Kosch M, Hohage H et al. Antihypertensive treatment in renal transplant patients – is there a role for ACE inhibitors? Ann Transplant 2001; 6: 31–7.
16. Baroletti SA, Gabardi S, Magee CC, Milford EL. Calcium channel blockers as the treatment of choice for hypertension in renal transplant recipients: fact or fiction. Pharmacotherapy 2003; 23: 788–801.
17. Noris M, Mister M, Pezzotta A et al. ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. Kidney Int 2003; 64: 2253–61.
18. Cross NB, Webster AC, Masson P et al. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 2009; 88: 7–18.
19. Parving HH, Persson F, Lewis JB et al. Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. N Engl J Med 2008; 358: 2433–46.
20. Persson F, Lewis JB, Lewis EJ et al. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol 2011; 6 (5): 1025–31.
21. Gansevoort RT, Sluiter WJ, Hemmelder MH et al. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10 (11): 1963–74.
22. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 259–305.
23. Del Castillo D, Campistol JM, Guirado L et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int Suppl 1998; 68: S135–S139.
24. Фомин И.В., Останина А.А., Поляков Д.С., Липатов К.С. Существует ли оптимальный уровень артериального давления у пациентов с терминальной хронической почечной недостаточностью до и после трансплантации почки? Совр. технологии в медицине. 2014; 6 (2): 53–60. / Fomin I.V., Ostanina A.A., Poliakov D.S., Lipatov K.S. Sushchestvuet li optimal'nyi uroven' arterial'nogo davleniia u patsientov s terminal'noi khronicheskoi pochechnoi nedostatochnost'iu do i posle transplantatsii pochki? Sovr. tekhnologii v meditsine. 2014; 6 (2): 53–60. [in Russian]
25. Paoletti E, Gherzi M, Amidone M et al. Association of arterial hypertension with renal target organ damage in kidney transplant recipients: the predictive role of ambulatory blood pressure monitoring. Transplantation 2009; 87: 1864–9.
26. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53: 217–22.
27. Мухин Н.А., Балкаров И.М., Моисеев В.С. и др. Хронические прогрессирующие нефропатии и образ жизни современного человека. Терапевт. арх. 2004; 9: 5–10. / Mukhin N.A., Balkarov I.M., Moiseev V.S. i dr. Khronicheskie progressiruiushchie nefropatii i obraz zhizni sovremennogo cheloveka. Terapevt. arkh. 2004; 9: 5–10. [in Russian]
28. Кобалава Ж.Д., Котовская Ю.В., Толкачева В.В., Мильто А.С. Мочевая кислота – ключевой компонент кардиренометаболического континуума. Кардиоваск. терапия и профилактика. 2008; 4: 95–100. / Kobalava Zh.D., Kotovskaia Iu.V., Tolkacheva V.V., Mil'to A.S. Mochevaia kislota – kliuchevoi komponent kardirenometabolicheskogo kontinuuma. Kardiovask. terapiia i profilaktika. 2008; 4: 95–100. [in Russian]
29. Parving HH, Brenner BM, McMurray JJV et al. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204–13.
30. Parving HH, Brenner BM, McMurray JJ et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst 2012; 13 (3): 387–93.
31. Mann JFE, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind controlled trial. Lancet 2008; 372: 547–53.
32. Inigo P, Campistol JM, Lario S et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta (1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 2001; 12: 822–7.
________________________________________________
2. Bikbov B.T., Tomilina N.A. Sostoianie zamestitel'noi terapii bol'nykh s khronicheskoi pochechnoi nedostatochnost'iu v Rossiiskoi Federatsii v 1998–2009 gg. (Otchet po dannym Rossiiskogo registra zamestitel'noi pochechnoi terapii). Nefrologiia i dializ. 2011; 13 (3). [in Russian]
3. Campistol JM, Romero R, Paul J, Gutieґrrez-Dalmaul А. Epidemiology of arterial hypertension in renal transplant patients: changes over the last decade. Nephrol Dial Transplant 2004; 19 (Suppl. 3): 62–6.
4. Kasiske BL, Cangro CB, Hariharan S et al. American Society of Transplantation. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2001; 1 (Suppl. 2): 3–95.
5. Curtis JJ. Hypertensinogenic mechanism of the calcineurin inhibitors. Curr Hypertens Rep 2002; 4: 377–80.
6. Mangus RS, Haag BW. Stented versus nonstented extravesical ureteroneocystostomy in renal transplantation: a metaanalysis. Am J Transplant 2004; 4 (11): 1889–96.
7. Pampaloni F, Sanchez LJ, Bencini L, Taddei G. Simultaneous aortoiliac reconstruction and renal transplantation: is it safe? Chir Ital 2002; 54(1): 115–20.
8. Cornell LD, Smith RN, Colvin RB. Kidney transplantation: mechanisms of rejection and acceptance. Annu Rev Pathol 2008; 3: 189–220.
9. Tomasoni S, Remuzzi G, Benigni A. Allograft rejection: acute and chronic studies. Contrib Nephrol 2008; 159: 122–34.
10. Webster AC, Woodroffe RC, Taylor RS et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331 (7520): 810.
11. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81 (9): 1234–48.
12. Lassila M. Interaction of cyclosporine A and the reninangiotensin system; new perspectives. Curr Drug Metab 2002; 3: 61–71.
13. Segura J, Garcia-Donair J, Praga M et al. Chronic kidney disease as a situation of high added risk in hypertensive patients J Am Soc Nephrol 2006; 17 (Suppl. 2.): 136–40.
14. Foley R, Murray A, Li S et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489–95.
15. Hausberg M, Kosch M, Hohage H et al. Antihypertensive treatment in renal transplant patients – is there a role for ACE inhibitors? Ann Transplant 2001; 6: 31–7.
16. Baroletti SA, Gabardi S, Magee CC, Milford EL. Calcium channel blockers as the treatment of choice for hypertension in renal transplant recipients: fact or fiction. Pharmacotherapy 2003; 23: 788–801.
17. Noris M, Mister M, Pezzotta A et al. ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. Kidney Int 2003; 64: 2253–61.
18. Cross NB, Webster AC, Masson P et al. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 2009; 88: 7–18.
19. Parving HH, Persson F, Lewis JB et al. Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. N Engl J Med 2008; 358: 2433–46.
20. Persson F, Lewis JB, Lewis EJ et al. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol 2011; 6 (5): 1025–31.
21. Gansevoort RT, Sluiter WJ, Hemmelder MH et al. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10 (11): 1963–74.
22. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 259–305.
23. Del Castillo D, Campistol JM, Guirado L et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int Suppl 1998; 68: S135–S139.
24. Fomin I.V., Ostanina A.A., Poliakov D.S., Lipatov K.S. Sushchestvuet li optimal'nyi uroven' arterial'nogo davleniia u patsientov s terminal'noi khronicheskoi pochechnoi nedostatochnost'iu do i posle transplantatsii pochki? Sovr. tekhnologii v meditsine. 2014; 6 (2): 53–60. [in Russian]
25. Paoletti E, Gherzi M, Amidone M et al. Association of arterial hypertension with renal target organ damage in kidney transplant recipients: the predictive role of ambulatory blood pressure monitoring. Transplantation 2009; 87: 1864–9.
26. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53: 217–22.
27. Mukhin N.A., Balkarov I.M., Moiseev V.S. i dr. Khronicheskie progressiruiushchie nefropatii i obraz zhizni sovremennogo cheloveka. Terapevt. arkh. 2004; 9: 5–10. [in Russian]
28. Kobalava Zh.D., Kotovskaia Iu.V., Tolkacheva V.V., Mil'to A.S. Mochevaia kislota – kliuchevoi komponent kardirenometabolicheskogo kontinuuma. Kardiovask. terapiia i profilaktika. 2008; 4: 95–100. [in Russian]
29. Parving HH, Brenner BM, McMurray JJV et al. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204–13.
30. Parving HH, Brenner BM, McMurray JJ et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst 2012; 13 (3): 387–93.
31. Mann JFE, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind controlled trial. Lancet 2008; 372: 547–53.
32. Inigo P, Campistol JM, Lario S et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta (1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 2001; 12: 822–7.
Авторы
А.А.Останина1, И.В.Фомин*2, Д.С.Поляков2, К.С.Липатов3, Г.А.Щербакова3
1 МБУЗ Городская больница №1. 663321, Россия, Норильск, п/о Оганер;
2 ГБОУ ВПО Нижегородская государственная медицинская академия Минздрава России. 603005, Россия, Нижний Новгород, пл. Минина и Пожарского, д. 10/1;
3 ФБУЗ Приволжский окружной медицинский центр ФМБА России. 603001, Россия, Нижний Новгород, Нижневолжская наб., д. 2
*fomin-i@yandex.ru
1 City Hospital №1. 663321, Russian Federation, Norilsk, p/о Oganer;
2 Nizhny Novgorod State Medical Academy of the Ministry of Health of the Russian Federation. 603005, Russian Federation, Nizhny Novgorod, pl. Minina I Pozharskogo, d. 10/1;
3 Volga District Medical Centre under Federal Medical and Biological Agency of Russia. 603001, Russian Federation, Nizhny Novgorod, Nizhnevolzhskaia nab., d. 2
*fomin-i@yandex.ru
1 МБУЗ Городская больница №1. 663321, Россия, Норильск, п/о Оганер;
2 ГБОУ ВПО Нижегородская государственная медицинская академия Минздрава России. 603005, Россия, Нижний Новгород, пл. Минина и Пожарского, д. 10/1;
3 ФБУЗ Приволжский окружной медицинский центр ФМБА России. 603001, Россия, Нижний Новгород, Нижневолжская наб., д. 2
*fomin-i@yandex.ru
________________________________________________
1 City Hospital №1. 663321, Russian Federation, Norilsk, p/о Oganer;
2 Nizhny Novgorod State Medical Academy of the Ministry of Health of the Russian Federation. 603005, Russian Federation, Nizhny Novgorod, pl. Minina I Pozharskogo, d. 10/1;
3 Volga District Medical Centre under Federal Medical and Biological Agency of Russia. 603001, Russian Federation, Nizhny Novgorod, Nizhnevolzhskaia nab., d. 2
*fomin-i@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.